Document is current

Article History

Received: 6 May 2025

Accepted: 30 June 2025

First Online: 15 July 2025

Declarations

:

: The study was performed in accordance with the Declaration of Helsinki and in compliance with good clinical practice guidelines and applicable laws. The protocol was approved by the institutional review board at study sites. Written informed consent was obtained before study entry from each patient or from the patient’s legally authorized representative if the patient was unable to provide consent.

: Not applicable.

: B.J.B. received funding from the American Society of Clinical Oncology Young Investigator Award and NIH K12 grant no. 5K12CA001727-27 and served on the advisory boards for Bristol Meyers Squibb, Rigel, Sanofi pharmaceuticals. W.X. is supported by a NIH K08 grant (K08CA267058). G.M. served as a scientific advisor for Ostentus Therapeutics. A.S.S. served as consultant for Syndax Bio and Debio Pharma. Y.B.N. is supported by the European Research Council (88352 ONCODESTROYER), the Adelson Medical Research Foundation and the Israel Cancer Research Fund Professorship. . R.L.L. is on the Supervisory board of Qiagen, a co-founder/board member at Ajax, and is a scientific advisor to Mission Bio, Zentalis, Auron, Prelude, and C4 Therapeutics; for each of these entities he receives equity. He has received research support from Calico, Zentalis and Ajax, and has consulted for Incyte, Astra Zeneca and Janssen. E.M.S. has served on the advisory boards of Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Amgen, Seattle Genetics, Syros Pharmaceuticals, Syndax Pharmaceuticals, Agios Pharmaceuticals, and Celgene, and is an equity holder in Auron Therapeutics. The remaining authors declare no competing financial interests.